PMID- 24692832
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140402
LR  - 20211021
IS  - 0011-393X (Print)
IS  - 0011-393X (Linking)
VI  - 70
IP  - 1
DP  - 2009 Feb
TI  - Comparative assessment of the effectiveness and tolerability of lornoxicam 8 mg 
      BID and diclofenac 50 mg TID in adult indian patients with osteoarthritis of the 
      hip or knee: A 4-week, double-blind, randomized, comparative, multicenter study.
PG  - 56-68
LID - 10.1016/j.curtheres.2009.02.006 [doi]
AB  - BACKGROUND: Reports of cardiovascular adverse events (AEs) associated with the 
      use of cyclooxygenase-2 inhibitors for the treatment of osteoarthritis (OA) have 
      prompted the quest for a better-tolerated NSAID. OBJECTIVE: The aim of this study 
      was to compare the effectiveness and tolerability of lornoxicam 8 mg BID and 
      diclofenac 50 mg TID in adult Indian patients with OA of the hip or knee. 
      METHODS: This 4-week, double-blind, randomized, comparative, multicenter study 
      was undertaken to compare oral lornoxicam and diclofenac in patients with OA. 
      Patients who met the selection criteria were enrolled consecutively from the 
      outpatient clinics of each of the participating hospitals in India. Participants 
      completed the Western Ontario and McMasters Individual Osteoarthritis Index 
      (WOMAC-OA), WOMAC Composite Index (WOMAC-CI) (for pain, stiffness, and physical 
      function), and a 10-cm visual analog scale (VAS) (0-10 where 0 = no pain and 10 = 
      worst possible pain or severe or excruciating pain) at each study visit (weeks 0 
      [baseline], 2, and 4 [or at early termination]). Patients' and physicians' global 
      assessments of arthritis control were measured at each study visit when 
      laboratory and clinical AEs were also monitored. The primary end points were the 
      WOMAC-OA, the WOMAC-CI, and VAS scores for pain among the patients who completed 
      the study. RESULTS: Of the 273 patients (159 men, 114 women; mean [SD] age, 44.73 
      [10.72] years; range, 28-68 years) enrolled in the study, 13 (7 in the lornoxicam 
      group and 6 in the diclofenac group) were lost to follow-up and their 
      effectiveness and tolerability results were not included in the study analysis. 
      Over the 4-week study period, both drugs provided significant (P < 0.05) 
      sustained relief of OA symptoms compared with baseline. Compared with baseline, 
      the mean pain score (WOMAC-CI) decreased 90.6% (13.88 [4.47] vs 1.30 [1.49]; P < 
      0.05) in the lornoxicam group and 88.9% (14.15 [4.56] vs 1.57 [1.49]; P < 0.05) 
      in the diclofenac group after 4 weeks of treatment. After 4 weeks of treatment, 
      the VAS pain score decreased from baseline 83.1% (8.04 [2.70] vs 1.36 [1.43]; P < 
      0.05) in the lornoxicam group and 79.3% (7.98 [2.98] vs 1.65 [1.47]; P < 0.05) in 
      the diclofenac group. Compared with baseline, the improvement rated at 2 weeks 
      was not significantly different between the 2 groups. Lornoxicam and diclofenac 
      were well tolerated. The rate of mild to moderate adverse gastrointestinal events 
      was not significantly different in the lornoxicam group compared with the 
      diclofenac group (14.6% vs 18.4%). Similarly, overall tolerability between the 2 
      groups was not significantly different. None of the patients experienced 
      cardiovascular AEs (eg, edema or increased blood pressure). CONCLUSION: The 
      results of the present study suggest that lornoxicam was comparable to diclofenac 
      in effectiveness and tolerability after 4 weeks of treatment in these adult 
      Indian patients with OA of the hip or knee who completed the study.
FAU - Goregaonkar, Arvind
AU  - Goregaonkar A
AD  - Department of Orthopedics, Lokmanya Tilak Municipal Medical College and General 
      Hospital, Sion, Mumbai, India.
FAU - Mathiazhagan, K J
AU  - Mathiazhagan KJ
AD  - Department of Orthopedic Surgery, M R Hospital, Chennai, India.
FAU - Shah, Ravindra R
AU  - Shah RR
AD  - Department of Orthopedics, Khwaja Banda Nawaz Institute of Medical Sciences, 
      Gulbarga, India.
FAU - Kapoor, Paramjeet Singh
AU  - Kapoor PS
AD  - Grecian Super-Specialty Hospital, Mohali, India.
FAU - Taneja, Praveen
AU  - Taneja P
AD  - RGS Healthcare Pvt. Ltd., Mohali, India.
FAU - Sharma, Akhilesh
AU  - Sharma A
AD  - Medical Services Department, Glenmark Pharmaceuticals Ltd., Mumbai, India.
FAU - Bolmall, Chandrashekhar
AU  - Bolmall C
AD  - Medical Services Department, Glenmark Pharmaceuticals Ltd., Mumbai, India.
FAU - Baliga, Vidyagauri P
AU  - Baliga VP
AD  - Medical Services Department, Glenmark Pharmaceuticals Ltd., Mumbai, India.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Ther Res Clin Exp
JT  - Current therapeutic research, clinical and experimental
JID - 0372621
PMC - PMC3969954
OTO - NOTNLM
OT  - India
OT  - diclofenac
OT  - lornoxicam
OT  - osteoarthritis
EDAT- 2009/02/01 00:00
MHDA- 2009/02/01 00:01
PMCR- 2009/02/01
CRDT- 2014/04/03 06:00
PHST- 2014/04/03 06:00 [entrez]
PHST- 2009/02/01 00:00 [pubmed]
PHST- 2009/02/01 00:01 [medline]
PHST- 2009/02/01 00:00 [pmc-release]
AID - S0011-393X(09)00018-6 [pii]
AID - 10.1016/j.curtheres.2009.02.006 [doi]
PST - ppublish
SO  - Curr Ther Res Clin Exp. 2009 Feb;70(1):56-68. doi: 
      10.1016/j.curtheres.2009.02.006.